Table 3 |
|||||||||||
|
Life Table representation of cumulative incidence of crude therapeutic failure attributable to drug resistance among subjects treated with chloroquine (CQ) and CQ + sulfadoxine/pyrimethamine (SP) without distinguishing recrudescence from reinfection |
|||||||||||
| CQ |
CQ+SP |
||||||||||
|
|
|||||||||||
| D |
N |
I |
W |
IR |
CIF |
D |
N |
I |
W |
IR |
CIF |
|
|
|||||||||||
| 0 |
29 |
0 |
0 |
0.00 |
0.00 |
0 |
88 |
0 |
0 |
0.00 |
0.00 |
| 2 |
29 |
0 |
0 |
0.00 |
0.00 |
2 |
88 |
0 |
2 |
0.00 |
0.00 |
| 4 |
29 |
0 |
0 |
0.00 |
0.00 |
4 |
86 |
1 |
1 |
0.01 |
0.01 |
| 7 |
29 |
0 |
0 |
0.00 |
0.00 |
7 |
84 |
1 |
0 |
0.01 |
0.02 |
| 11 |
29 |
1 |
0 |
0.03 |
0.03 |
11 |
83 |
0 |
0 |
0.00 |
0.02 |
| 14 |
28 |
2 |
1 |
0.07 |
0.10 |
14 |
83 |
0 |
0 |
0.00 |
0.02 |
| 18 |
25 |
2 |
1 |
0.08 |
0.18 |
18 |
83 |
0 |
2 |
0.00 |
0.02 |
| 21 |
22 |
2 |
2 |
0.10 |
0.26 |
21 |
81 |
0 |
1 |
0.00 |
0.02 |
| 28 |
18 |
4 |
0 |
0.22 |
0.42 |
28 |
80 |
3 |
1 |
0.04 |
0.06 |
|
|
|||||||||||
|
N = sample at risk of therapeutic failure at start of interval i = the number of cases of therapeutic failure during the interval w = the number of subjects withdrawn from the test during the interval due to exclusion from analysis, loss to follow-up after latest blood smear, intercurrent infection with another plasmodia species, or reinfection by different genotype P. falciparum or relapse/reinfection by P. vivax based on day of recurrent parasitemia CQ +DCQ concentrations IR = risk of therapeutic failure in the interval, calculated as i/(N-w/2) CIF = cumulative incidence of therapeutic failure, calculated as 1-[(1-IRn)(1-CIFn-1)], where IRn is the IR in the current interval and CIFn-1 is the cumulative incidence up to the previous interval |
|||||||||||
|
Lederman et al. Malaria Journal 2006 5:108 doi:10.1186/1475-2875-5-108 |
|||||||||||
